AMD

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

The endorsement follows FDA approval in the United States this summer.

These companies will be among those sharing information and data in Boston, Massachusetts November 14-16, 2023.

Researchers found the growth of RPE cells was successfully controlled by the stencil patterns. When RPE cells were not held together correctly, the cells excreted levels of harmful proteins that could contribute to vision loss.

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Modern Retina about the pegcetacoplan GALE extension study for geographic atrophy. She also shared insights regarding her career transition, underscoring the significance of mentorship and a passion for one's work during this year's American Academy of Ophthalmology meeting in San Francisco.

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.

According to the study, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.

Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.

The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

This gene therapy is designed to be a one-time intravitreally therapy that has demonstrated potent efficacy and a favorable safety profile in preclinical studies.

This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.

In the data shared, switching to SB15 from AFL maintained comparable clinical efficacy and safety in treating patients with neovascular age-related macular degeneration (nAMD), confirming biosimilarity between these agents before and after switching.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

Nathan Steinle, MD, spoke with Modern Retina's editor to give insights into his Retina Society presentation titled, "Phase 3 studies of dual inhibition of VEGF C/D and VEGF A using OPT-302 in combination With ranibizumab (ShORe Trial) or aflibercept (COAST Trial) in neovascular AMD."

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

According to the company, a change from base line best corrected visual acuity based on an average at week 44, 48 and 52 serves as the primary endpoint.

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD."

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.